Clinical Pharmacokinetics and Pharmacodynamics of Isepamicin
暂无分享,去创建一个
[1] M. Tod,et al. Isepamicin in intensive care unit patients with nosocomial pneumonia: population pharmacokinetic-pharmacodynamic study. , 1999, The Journal of antimicrobial chemotherapy.
[2] F. Torricelli,et al. Inherited susceptibility to aminoglycoside ototoxicity: genetic heterogeneity and clinical implications. , 1999, American journal of otolaryngology.
[3] G. Drusano,et al. Optimizing Aminoglycoside Therapy for Nosocomial Pneumonia Caused by Gram-Negative Bacteria , 1999, Antimicrobial Agents and Chemotherapy.
[4] M. Barclay,et al. Once Daily Aminoglycoside Therapy , 1999, Clinical pharmacokinetics.
[5] J. Schacht,et al. Stimulation of free radical formation by aminoglycoside antibiotics 1 The data in this paper have been presented, in part, at the meeting of the Association for Research in Otolaryngology, February 1996. 1 , 1999, Hearing Research.
[6] J. Aran,et al. Attenuation of aminoglycoside-induced cochlear damage with the metabolic antioxidant α-lipoic acid , 1999, Hearing Research.
[7] J. Schacht,et al. Iron chelators protect from aminoglycoside-induced cochleo- and vestibulo-toxicity. , 1998, Free radical biology & medicine.
[8] D. Nicolau,et al. The pharmacodynamics of aminoglycosides. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] S. Komune,et al. Isepamicin Sulfate-Induced Sensorineural Hearing Loss in Patients with the 1555 A→G Mitochondrial Mutation , 1998, ORL.
[10] B. Uzzan,et al. Population Pharmacokinetic Study of Amikacin Administered Once or Twice Daily to Febrile, Severely Neutropenic Adults , 1998, Antimicrobial Agents and Chemotherapy.
[11] J. Izquierdo,et al. Postantibiotic and Sub-MIC Effects of Azithromycin and Isepamicin against Staphylococcus aureus and Escherichia coli , 1998, Antimicrobial Agents and Chemotherapy.
[12] D. Izard,et al. [Sensitivity of Pseudomonas aeruginosa to amikacin and to isepamicin in surgery and in intensive care]. , 1997, Pathologie-biologie.
[13] K. Shaw,et al. Cloning and characterization of an aminoglycoside 6'-N-acetyltransferase gene from Citrobacter freundii which confers an altered resistance profile , 1997, Antimicrobial agents and chemotherapy.
[14] A. Nomeir,et al. Pharmacokinetics of isepamicin following a single administration by intravenous infusion or intramuscular injections , 1997, Antimicrobial agents and chemotherapy.
[15] P. Speelman,et al. Circadian variations in serum levels and the renal toxicity of aminoglycosides in patients , 1997, Clinical pharmacology and therapeutics.
[16] J. Rotschafer,et al. Editorial Response: Single Daily Dosing of Aminoglycosides—A Concept Whose Time Has Not Yet Come , 1997 .
[17] D. Gilbert. Meta-analyses are no longer required for determining the efficacy of single daily dosing of aminoglycosides. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] R. Hatala,et al. Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] A. Bayer,et al. Adaptive resistance of Pseudomonas aeruginosa induced by aminoglycosides and killing kinetics in a rabbit endocarditis model , 1997, Antimicrobial agents and chemotherapy.
[20] M. Cayen,et al. Pharmacokinetics of intramuscularly administered isepamicin in man. , 1997, Chemotherapy.
[21] Claude Carbón,et al. Resistance to amikacin and isepamicin in rabbits with experimental endocarditis of an aac(6')-Ib-bearing strain of Klebsiella pneumoniae susceptible in vitro , 1996, Antimicrobial agents and chemotherapy.
[22] P. Speelman,et al. Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy , 1996, Antimicrobial agents and chemotherapy.
[23] M. Tod,et al. Population pharmacokinetic study of isepamicin with intensive care unit patients , 1996, Antimicrobial agents and chemotherapy.
[24] P. Glue,et al. Effect of age on the pharmacokinetics of isepamicin, a new once daily aminoglycoside , 1996 .
[25] R. Colucci,et al. The effect of renal function on felbamate clearance , 1996 .
[26] M. Cayen,et al. Pharmacokinetics of intravenously administered isepamicin in men , 1995, Antimicrobial agents and chemotherapy.
[27] Eric M. Priuska,et al. Formation of free radicals by gentamicin and iron and evidence for an iron/gentamicin complex. , 1995, Biochemical pharmacology.
[28] A. Nomeir,et al. Pharmacokinetics and metabolism of 14C-isepamicin in humans following intravenous administration , 1995, Antimicrobial agents and chemotherapy.
[29] D. Blum. An overview of the safety of isepamicin in adults. , 1995, Journal of chemotherapy.
[30] E. Ongini,et al. Auditory impairment in guinea pigs treated with isepamicin. , 1995, Journal of chemotherapy.
[31] W. H. Barr,et al. Pharmacokinetics of isepamicin. , 1995, Journal of chemotherapy.
[32] G. Beaucaire. Evaluation of the efficacy and safety of isepamicin compared with amikacin in the treatment of nosocomial pneumonia and septicaemia. , 1995, Journal of chemotherapy.
[33] V. Leblond,et al. Isepamicin once daily plus ceftriaxone versus amikacin plus ceftriaxone in febrile neutropenic patients. , 1995, Journal of chemotherapy.
[34] R. Jones. Isepamicin (SCH 21420, 1-N-HAPA gentamicin B): microbiological characteristics including antimicrobial potency of spectrum of activity. , 1995, Journal of chemotherapy.
[35] K. Shaw,et al. The changing nature of aminoglycoside resistance mechanisms and the role of isepamicin--a new broad-spectrum aminoglycoside. The Aminoglycoside Resistance Study Groups. , 1995, Journal of chemotherapy.
[36] W. Craig,et al. Once-daily versus multiple-daily dosing of aminoglycosides. , 1995, Journal of chemotherapy.
[37] C H Nightingale,et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients , 1995, Antimicrobial agents and chemotherapy.
[38] R. Brasseur,et al. Molecular parameters involved in aminoglycoside nephrotoxicity. , 1995, Journal of toxicology and environmental health.
[39] Jerome J. Schentag,et al. The Importance of Pharmacokinetic/Pharmacodynamic Surrogate Markers to Outcome , 1995, Clinical pharmacokinetics.
[40] P. Kosmidis,et al. A comparative study with two administration schedules of leucovorin and 5-fluorouracil in advanced colorectal cancer. , 1995, Journal of chemotherapy.
[41] H. Georges,et al. Amikacin levels in bronchial secretions of 10 pneumonia patients with respiratory support treated once daily versus twice daily , 1995, Antimicrobial agents and chemotherapy.
[42] K. Shaw,et al. The most frequently occurring aminoglycoside resistance mechanisms--combined results of surveys in eight regions of the world. The Aminoglycoside Resistance Study Groups. , 1995, Journal of chemotherapy.
[43] G. Cortopassi,et al. Proposed molecular and cellular mechanism for aminoglycoside ototoxicity , 1994, Antimicrobial Agents and Chemotherapy.
[44] J. Schacht,et al. Sulfhydryl compounds and antioxidants inhibit cytotoxicity to outer hair cells of a gentamicin metabolite in vitro , 1994, Hearing Research.
[45] R. Farinotti,et al. Activity of isepamicin and selection of permeability mutants to beta-lactams during aminoglycoside therapy of experimental endocarditis due to Klebsiella pneumoniae CF104 producing an aminoglycoside acetyltransferase 6' modifying enzyme and a TEM-3 beta-lactamase. , 1994, The Journal of infectious diseases.
[46] T. Uematsu. Population pharmacokinetic analysis of new aminoglycosides, astromicin and isepamicin, and evaluation of Bayesian prediction method for approximation of individual clearance of drug. , 1993, International journal of clinical pharmacology, therapy, and toxicology.
[47] J. Flandrois,et al. A statistical evaluation of the bactericidal effects of ceftibuten in combination with aminoglycosides and ciprofloxacin. , 1993, The Journal of antimicrobial chemotherapy.
[48] Yasufumi Sato,et al. Effect of Hemodialysis on Serum Concentration of Isepamicin in a Patient with Endstage Renal Failure , 1993, The Annals of pharmacotherapy.
[49] M. Paesmans,et al. Efficacy and Toxicity of Single Daily Doses of Amikacin and Ceftriaxone versus Multiple Daily Doses of Amikacin and Ceftazidime for Infection in Patients with Cancer and Granulocytopenia , 1993, Annals of Internal Medicine.
[50] F. Luft,et al. Calcium antagonists and renal protection. , 1993, Renal failure.
[51] R. Bryant,et al. Beta-lactam enhancement of aminoglycoside activity under conditions of reduced pH and oxygen tension that may exist in infected tissues. , 1992, The Journal of infectious diseases.
[52] J. McCormack,et al. A critical reevaluation of the "therapeutic range" of aminoglycosides. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[53] L. Kaufman,et al. Effect of isepamicin dosing scheme on concentration in cochlear tissue , 1991, Antimicrobial Agents and Chemotherapy.
[54] C. Halstenson,et al. Isepamicin disposition in subjects with various degrees of renal function , 1991, Antimicrobial Agents and Chemotherapy.
[55] R. Jones,et al. Antimicrobial activity of isepamicin (SCH21420, 1-N-HAPA gentamicin B) combinations with cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, imipenem, mezlocillin and piperacillin tested against gentamicin-resistant and susceptible gram-negative bacilli and enterococci. , 1991, Journal of chemotherapy.
[56] W. Craig,et al. Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against gram-negative bacilli. , 1991, The Journal of antimicrobial chemotherapy.
[57] G. Jackson,et al. First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use , 1991, Antimicrobial Agents and Chemotherapy.
[58] W. Craig,et al. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. , 1991, The Journal of antimicrobial chemotherapy.
[59] S. Norrby. Treatment failures with broad-spectrum antibiotics. , 1991, Scandinavian journal of infectious diseases. Supplementum.
[60] E. Ongini,et al. Simple measurement of isepamicin, a new aminoglycoside antibiotic, in guinea pig and human plasma, using high-performance liquid chromatography with ultraviolet detection. , 1991, Therapeutic drug monitoring.
[61] G. Matzke,et al. Effect of concomitant administration of piperacillin on the dispositions of netilmicin and tobramycin in patients with end-stage renal disease , 1990, Antimicrobial Agents and Chemotherapy.
[62] W. Awni,et al. High-performance liquid chromatographic determination of isepamicin in plasma, urine and dialysate. , 1990, Journal of chromatography.
[63] M. D. de Broe,et al. Once‐daily dosing decreases renal accumulation of gentamicin and netilmicin , 1989, Clinical pharmacology and therapeutics.
[64] M. Nakashima,et al. Evaluation of a Fluorescence Polarization Immunoassay Procedure for Quantitation of Isepamicin, a New Aminoglycoside Antibiotic , 1988, Therapeutic drug monitoring.
[65] J. Turnidge,et al. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. , 1988, The Journal of infectious diseases.
[66] Sally E. Williams,et al. Three molecular steps of aminoglycoside ototoxicity demonstrated in outer hair cells , 1987, Hearing Research.
[67] J. Blaser,et al. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance , 1987, Antimicrobial Agents and Chemotherapy.
[68] Jerome J. Schentag,et al. Single-dose accumulation pharmacokinetics of tobramycin and netilmicin in normal volunteers , 1987, Antimicrobial Agents and Chemotherapy.
[69] R. Moore,et al. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. , 1987, The Journal of infectious diseases.
[70] J. E. Murphy,et al. Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides. , 1986, Clinical pharmacy.
[71] M. D. de Broe,et al. In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. , 1986, The Journal of pharmacology and experimental therapeutics.
[72] J. Sculier,et al. Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia. , 1984, The American journal of medicine.
[73] J. Longstreth,et al. Netilmicin and gentamicin multidose kinetics in normal subjects , 1983, Clinical pharmacology and therapeutics.
[74] A. Astier,et al. [Pharmacokinetics of gentamicin in the decompensed alcoholic cirrhotic patient. Therapeutic consequences]. , 1983, Pathologie-biologie.
[75] Everett Ed,et al. Endobronchial pH. Relevance of aminoglycoside activity in gram-negative bacillary pneumonia. , 1983 .
[76] R. Jones,et al. Comparison of in vitro activity of Sch 21420, a gentamicin B derivative, with those of amikacin, gentamicin, netilmicin, sisomicin, and tobramycin , 1980, Antimicrobial Agents and Chemotherapy.
[77] A. Kucers. Use of Antibiotics , 1979 .
[78] P. Lacy,et al. Effect of ethanol and n-butanol on alloxan inhibition of glucose-induced insulin release in isolated pancreatic islets. , 1978, Biochemical pharmacology.